CD137 (TNFRSF9)
(Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))
Type de proteíne
Recombinant
Activité biologique
Active
Attributs du protein
AA 24-211
Origine
Souris
Source
HEK-293 Cells
Purification/Conjugué
Cette CD137 protéine est marqué à la His tag.
Application
Functional Studies (Func)
Séquence
AA 24-211
Attributs du produit
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 22 kDa. The protein migrates as 35-40 kDa under reducing (R) condition (SDS-PAGE).
TNFRSF9
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
ELISA, FACS
TNFRSF9 Protein, zgc:136557 Protein, 4-1BB Protein, CD137 Protein, CDw137 Protein, ILA Protein, A930040I11Rik Protein, AA408498 Protein, AI325004 Protein, Cd137 Protein, Ly63 Protein, tumor necrosis factor receptor superfamily member 9 Protein, TNF receptor superfamily member 9 Protein, tumor necrosis factor receptor superfamily, member 9a Protein, tumor necrosis factor receptor superfamily, member 9 Protein, TNFRSF9 Protein, tnfrsf9a Protein, Tnfrsf9 Protein
Sujet
4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.